Clinical Trial Update: A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity [Phase 2]

View source ↗

Summary

A Phase II study evaluating amifostine to prevent acute radiation-induced rectal toxicity in rectal cancer patients. The registry status is listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Amifostine (amifostine)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN